Summary of the Interview with Dr. Castillo on Advanced Gastric Cancer Treatment
This interview with dr. Castillo focuses on a study examining the effectiveness of combining chemotherapy with immune checkpoint inhibitors for HER2-negative advanced gastric cancer, highlighting the importance of personalized treatment approaches. Here’s a breakdown of the key takeaways:
study Aim:
* to assess the impact of chemotherapy plus immunotherapy on patient outcomes in advanced gastric cancer, specifically looking at differences based on metastatic sites (peritoneal vs. non-peritoneal, liver mass vs. no liver mass).
* To understand the role of patient heterogeneity in treatment response.
Key Findings:
* Gastric cancer is highly heterogeneous: different subtypes and the Lauren histology type influence outcomes.
* Tumor microenvironment matters: The location of metastasis (e.g., peritoneal disease, liver mass) significantly impacts treatment response.
* Chemotherapy + immunotherapy benefits patients with liver mass: Patients with liver metastasis generally benefit from this combination.
* Peritoneal disease is a challenge: The study found no meaningful benefit from chemotherapy + immunotherapy specifically for patients with peritoneal disease.
* Need for further research: More studies are needed to understand why immunotherapy and chemotherapy may not be as effective in certain subgroups.
Implications for Treatment Decisions:
* NCCN Guidelines: Current guidelines recommend chemo and immunotherapy as first-line treatment.
* Peritoneal disease Requires Special Consideration: For patients with extensive peritoneal disease, Dr. Castillo recommends:
* Referral to specialized academic centers: These centers offer multidisciplinary programs and innovative treatments like HIPEC (hyperthermic intraperitoneal chemotherapy).
* Immunotherapy Options: different immunotherapies (tislelizumab, pembrolizumab, nivolumab) may have varying responses, and a side-by-side comparison is needed to guide physician choice.
* Patient Dialogue: Doctors should clearly explain the available studies and expectations to patients.
* Poor Prognosis: Gastric cancer with peritoneal disease currently has a poor prognosis.
Overall Message:
The study emphasizes that a “one-size-fits-all” approach to treating advanced gastric cancer is not effective. Treatment strategies need to be tailored to the individual patient, considering the specific characteristics of their cancer and metastatic sites. Early referral to specialized centers and participation in clinical trials are crucial for improving outcomes.
Keep reading